A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen

• Egile Nagusiak: Thomas Kimble (Egilea), Anne E. Burke (Egilea), Kurt T. Barnhart (Egilea), David F. Archer (Egilea), Enrico Colli (Egilea), Carolyn L. Westhoff (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2020-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objectives: To evaluate contraceptive effectiveness and safety of oral drospirenone 4 mg 24/4-day regimen in the United States. Study design: We performed a prospective, single-arm, multicenter phase 3 trial in sexually active women for up to thirteen 28-day treatment cycles. Primary outcome was the...